[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 41 of about 41

Advertisement
4. Levitt NC, Propper DJ, Madhusudan S, Braybrooke JP, Echeta C, Te Poele R, Davies SL, Flanagan E, Hickson ID, Joel S, Ganesan TS: Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer. Br J Cancer; 2005 Jul 11;93(1):60-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer.
  • A pharmacokinetically guided phase I study of topotecan and etoposide phosphate was conducted in recurrent ovarian cancer.
  • All patients had recurrent disease following prior platinum-containing chemotherapy.
  • Treatment was with topotecan intravenously for 5 days followed immediately by a 5-day intravenous infusion of etoposide phosphate (EP), with pharmacokinetically guided dose adjustment.
  • Plasma etoposide levels were measured on days 2 and 4 of the infusion.
  • The maximum-tolerated dose was topotecan 0.85 mg m(-2) day(-1) days 1-5 followed immediately by a 5-day infusion of EP at a plasma concentration of 1 mug ml(-1).
  • This regimen of topotecan followed by EP demonstrated good activity in recurrent ovarian cancer and was noncrossresistant with paclitaxel.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antigens, Neoplasm / blood. DNA Topoisomerases, Type II / blood. DNA-Binding Proteins / blood. Etoposide / administration & dosage. Etoposide / adverse effects. Etoposide / analogs & derivatives. Etoposide / pharmacokinetics. Female. Humans. Middle Aged. Organophosphorus Compounds / administration & dosage. Organophosphorus Compounds / adverse effects. Organophosphorus Compounds / pharmacokinetics. Quality of Life. Recurrence. Topotecan / administration & dosage. Topotecan / adverse effects. Topotecan / pharmacokinetics

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Jan;18(1):106-15 [10623700.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):699-708 [10793106.001]
  • [Cites] Gynecol Oncol. 2000 Oct;79(1):116-9 [11006042.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Feb;85(4):1086-90 [2829215.001]
  • [Cites] J Clin Oncol. 1989 Mar;7(3):396-401 [2918334.001]
  • [Cites] Cancer Res. 1991 Feb 15;51(4):1129-36 [1705167.001]
  • [Cites] Cell Growth Differ. 1991 Apr;2(4):209-14 [1651102.001]
  • [Cites] Int J Cancer. 1992 Mar 12;50(5):760-6 [1312063.001]
  • [Cites] Exp Cell Res. 1992 Jun;200(2):452-9 [1315288.001]
  • [Cites] Eur J Cancer. 1992;28A(4-5):743-8 [1326304.001]
  • [Cites] Ann Oncol. 1993 Aug;4(7):529-32 [8395869.001]
  • [Cites] J Clin Oncol. 1994 Jan;12(1):60-3 [8270985.001]
  • [Cites] Br J Cancer. 1994 Jan;69(1):191-5 [8286205.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1994;34:191-218 [8042851.001]
  • [Cites] J Biol Chem. 1995 Sep 15;270(37):21429-32 [7665550.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1552-7 [8622071.001]
  • [Cites] J Clin Oncol. 1996 Jun;14(6):1903-12 [8656259.001]
  • [Cites] Cytometry. 1996 Nov 1;25(3):205-10 [8914817.001]
  • [Cites] Cancer Chemother Pharmacol. 2001;47(2):141-8 [11269740.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):1893-900 [11283120.001]
  • [Cites] J Clin Oncol. 2001 Jun 1;19(11):2865-74 [11387359.001]
  • [Cites] J Clin Oncol. 2001 Jul 15;19(14):3312-22 [11454878.001]
  • [Cites] Semin Oncol. 1996 Oct;23(5 Suppl 12):40-7 [8941409.001]
  • [Cites] J Clin Oncol. 1996 Dec;14(12):3056-61 [8955650.001]
  • [Cites] Ann N Y Acad Sci. 1996 Dec 13;803:306-7 [8993524.001]
  • [Cites] Cancer Chemother Pharmacol. 1996;39(1-2):109-12 [8995507.001]
  • [Cites] Cancer Res. 1997 Apr 15;57(8):1425-8 [9108439.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2183-93 [9196130.001]
  • [Cites] Br J Cancer. 1997;76(11):1500-8 [9400949.001]
  • [Cites] Semin Oncol. 1997 Dec;24(6 Suppl 20):S20-3-S20-10 [9425956.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):405-10 [9469322.001]
  • [Cites] Clin Cancer Res. 1998 Jun;4(6):1459-67 [9626463.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3345-52 [9779711.001]
  • [Cites] Ann Oncol. 1998 Nov;9(11):1205-11 [9862051.001]
  • [Cites] Eur J Cancer. 1998 Sep;34(10):1514-21 [9893622.001]
  • [Cites] Leukemia. 1999 Mar;13(3):343-7 [10086724.001]
  • [Cites] Oncology. 2001;61 Suppl 1:25-9 [11598411.001]
  • [Cites] Ann Oncol. 2001 Nov;12(11):1567-73 [11822756.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 May;49(5):347-55 [11976828.001]
  • [Cites] Leuk Lymphoma. 2002 May;43(5):989-99 [12148910.001]
  • [Cites] Cancer. 2002 Oct 1;95(7):1511-9 [12237920.001]
  • [Cites] Lancet. 2002 Aug 17;360(9332):505-15 [12241653.001]
  • [Cites] Leuk Lymphoma. 2002 Aug;43(8):1581-7 [12400600.001]
  • [Cites] Gynecol Oncol. 2003 Sep;90(3 Pt 2):S8-15 [13129490.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4682-8 [14581337.001]
  • [Cites] J Chromatogr. 1985 May 3;339(2):419-23 [4008582.001]
  • [Cites] J Biol Chem. 1985 Nov 25;260(27):14873-8 [2997227.001]
  • [Cites] Eur J Cancer Clin Oncol. 1985 Nov;21(11):1315-9 [3000790.001]
  • (PMID = 15956976.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; 0 / Organophosphorus Compounds; 528XYJ8L1N / etoposide phosphate; 6PLQ3CP4P3 / Etoposide; 7M7YKX2N15 / Topotecan; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Other-IDs] NLM/ PMC2361471
  •  go-up   go-down


5. Golenkov AK, Mitina TA, Kogarko IN, Liubimova NV, Klinushkina EF, Baryshnikov AIu: [Pharmacodynamic characteristics of velcade efficacy in resistant and recurrent multiple myeloma: determination of free light chains of blood serum immunoglobulins]. Ter Arkh; 2009;81(7):37-41
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pharmacodynamic characteristics of velcade efficacy in resistant and recurrent multiple myeloma: determination of free light chains of blood serum immunoglobulins].
  • AIM: To ascertain individual sensitivity to velkeid in patients with resistant and recurrent multiple myeloma (MM) by determination of free light chains (FLC) of serum immunoglobulins.
  • MATERIAL AND METHODS: Fourteen patients with MM stage III (Gcappa-5, Glambda-2, Acappa-3, Alambda-1, BJcappa-3) aged 52-75 years with documented resistance to treatment or recurrence received second-line monotherapy with velkeid.
  • The drug was injected intravenously (jet) in a dose 1.3 mg/m2 on the treatment day 1, 4, 8 and 11.
  • Free light chains concentration was examined with antibodies to their latent determinants (Binding Site, UK) on nephelometer (Hitathi-911, Japan) on velkeid treatment day 1, 2, 3, 5, 9 and 12.
  • RESULTS: Nine patients showed lowering of FLC concentration and responded to treatment by Durie criteria.
  • CONCLUSION: Dynamic follow-up of FLC concentration of the tumor clone in resistant and recurrent MM evaluates pharmacodynamics of the drug.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Boronic Acids / therapeutic use. Drug Resistance, Neoplasm / drug effects. Immunoglobulin Light Chains / blood. Multiple Myeloma / drug therapy. Pyrazines / therapeutic use
  • [MeSH-minor] Aged. Bortezomib. Drug Administration Schedule. Humans. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Recurrence

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19708571.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Immunoglobulin Light Chains; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


6. Morgan RJ, Synold T, Mamelak A, Lim D, Al-Kadhimi Z, Twardowski P, Leong L, Chow W, Margolin K, Shibata S, Somlo G, Yen Y, Frankel P, Doroshow JH: Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors. Cancer Chemother Pharmacol; 2010 Oct;66(5):927-33
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors.
  • PURPOSE: This study was designed to ascertain the dose-limiting toxicities (DLT) and maximally tolerated doses of the combination of fixed-dose tamoxifen and carboplatin, with escalating doses of topotecan, and to determine the pharmacokinetics of topotecan in the plasma and cerebrospinal fluid.
  • RESULTS: Seventeen patients received 39 cycles of treatment: median 2, (range 1-5).
  • The tumors included glioblastoma (6), anaplastic astrocytoma (2), metastatic non-small cell (3), small cell lung (2), and one each with medulloblastoma, ependymoma, and metastatic breast or colon carcinoma.
  • Topotecan levels, total and lactone, were measured prior to the end of infusion in plasma and cerebrospinal fluid (CSF).
  • At 1.0 mg/m(2)/d, the median CSF/plasma ratio was 19.4% (range 15.1-59.1%).
  • The total plasma topotecan in two pts with DLTs was 4.63 and 5.87 ng/ml, in three without DLTs at the same dose level the mean total plasma topotecan was 3.4 ng/ml (range 3.02-3.83).
  • Plasma lactone levels were 33% of the total; CSF penetration was 20% of the total plasma levels.
  • One patient with metastatic non-small cell and one with small cell lung cancer had objective PRs.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. Topotecan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Anticancer Drugs. 1998 Aug;9(7):581-6 [9773800.001]
  • [Cites] J Neurooncol. 1999 Feb;41(3):285-9 [10359149.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):208-15 [18316473.001]
  • [Cites] Eur J Pharmacol. 2001 Jan 19;412(1):21-5 [11166732.001]
  • [Cites] Cancer Invest. 2002;20(3):293-302 [12025223.001]
  • [Cites] Cancer. 2003 May 1;97(9 Suppl):2381-6 [12712460.001]
  • [Cites] Cancer. 1982 Jan 1;49(1):12-8 [6274499.001]
  • [Cites] Onkologie. 1983 Apr;6(2):58-61 [6223253.001]
  • [Cites] J Neurooncol. 1983;1(2):139-44 [6678966.001]
  • [Cites] Int J Cancer. 1988 Sep 15;42(3):382-8 [3417367.001]
  • [Cites] Cancer Chemother Pharmacol. 1990;25(5):382-3 [2407368.001]
  • [Cites] Br J Cancer. 1991 Apr;63(4):641-5 [2021551.001]
  • [Cites] Cancer Res. 1991 Sep 15;51(18):4837-44 [1893376.001]
  • [Cites] J Neurooncol. 1991 Apr;10(2):173-7 [1716670.001]
  • [Cites] Cancer. 1992 Feb 15;69(4):972-80 [1735089.001]
  • [Cites] Cancer Metastasis Rev. 1991 Dec;10(4):335-41 [1786634.001]
  • [Cites] Neurosurgery. 1992 Jun;30(6):897-902; discussion 902-3 [1377370.001]
  • [Cites] Cancer Chemother Pharmacol. 1992;30(4):251-60 [1643692.001]
  • [Cites] Invest New Drugs. 1992 Nov;10(4):239-53 [1487397.001]
  • [Cites] Neurosurgery. 1993 Mar;32(3):485-9; discussion 489-90 [8384328.001]
  • [Cites] Eur J Cancer. 1993;29A(12):1696-9 [7691116.001]
  • [Cites] Cancer Res. 1994 Oct 1;54(19):5118-22 [7923128.001]
  • [Cites] Cancer Chemother Pharmacol. 1996;37(3):195-202 [8529278.001]
  • [Cites] J Natl Cancer Inst. 1996 Jun 5;88(11):734-41 [8637027.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(2):215-20 [8686548.001]
  • [Cites] Cancer. 1996 Aug 1;78(3):527-31 [8697400.001]
  • [Cites] J Chromatogr B Biomed Appl. 1996 Apr 12;678(2):309-15 [8738036.001]
  • [Cites] Neurosurgery. 1996 Mar;38(3):587-90; discussion 590-1 [8837815.001]
  • [Cites] J Clin Oncol. 1996 Dec;14(12):3074-84 [8955652.001]
  • [Cites] Am J Clin Oncol. 1997 Jun;20(3):303-7 [9167759.001]
  • [Cites] J Neurooncol. 1997 Nov;35(2):161-7 [9266454.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3121-8 [9294475.001]
  • [Cites] Semin Oncol. 1997 Aug;24(4 Suppl 12):S12-52-S12-55 [9331122.001]
  • [Cites] Semin Oncol. 1997 Dec;24(6 Suppl 20):S20-11-S20-26 [9425957.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;41(4):307-16 [9488600.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;41(5):385-90 [9523734.001]
  • [Cites] J Neurooncol. 1998 May;38(1):59-68 [9540058.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1998 May;78(1):91-3 [9605456.001]
  • [Cites] Clin Cancer Res. 1996 Apr;2(4):619-22 [9816211.001]
  • (PMID = 20107803.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA033572; United States / NCI NIH HHS / CA / P30 CA033572-26; United States / NCI NIH HHS / CA / CA 33572
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 094ZI81Y45 / Tamoxifen; 7M7YKX2N15 / Topotecan; BG3F62OND5 / Carboplatin
  • [Other-IDs] NLM/ NIHMS335377; NLM/ PMC3265324
  •  go-up   go-down


7. Mitina TA, Golenkov AK: [Clinical characteristics of velcade cumulative effect in resistant and recurrent multiple myeloma]. Ter Arkh; 2008;80(7):48-50
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics of velcade cumulative effect in resistant and recurrent multiple myeloma].
  • AIM: To assess efficacy of velcade monotherapy in patients with resistent and recurrent multiple myeloma (MM).
  • MATERIAL AND METHODS: Velcade was given to 29 patients (11 males and 18 females at the age 41-73 years) with resistant and recurrent MM of stage 3.
  • RESULTS: After, on the average, 3 courses of velcade therapy PIg reduction was 31.3%.
  • After 3 cycles of velcade therapy in 29 patients an objective response occurred in 48%, after 6 cycles it increased to 56.5%.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Boronic Acids / therapeutic use. Drug Resistance, Neoplasm. Multiple Myeloma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Pyrazines / therapeutic use
  • [MeSH-minor] Adult. Aged. Bortezomib. Disease Progression. Dose-Response Relationship, Drug. Female. Humans. Incidence. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18763595.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


8. Puduvalli VK, Yung WK, Hess KR, Kuhn JG, Groves MD, Levin VA, Zwiebel J, Chang SM, Cloughesy TF, Junck L, Wen P, Lieberman F, Conrad CA, Gilbert MR, Meyers CA, Liu V, Mehta MP, Nicholas MK, Prados M, North American Brain Tumor Consortium: Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. J Clin Oncol; 2004 Nov 1;22(21):4282-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study.
  • This two-stage phase II trial was conducted to determine the efficacy of fenretinide in adults with recurrent malignant gliomas.
  • PATIENTS AND METHODS: Twenty-two patients with anaplastic gliomas (AG) and 23 patients with glioblastoma (GBM) whose tumors had recurred after radiotherapy and no more than two chemotherapy regimens were enrolled.
  • The first-administration mean plasma C(max) for fenretinide was 832 +/- 360 ng/mL at the 600 mg/m(2) bid dosage and 1,213 +/- 261 ng/mL at the 900 mg/m(2) bid dosage.
  • CONCLUSION: Fenretinide was inactive against recurrent malignant gliomas at the dosage used in this trial.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1979 Oct;5(10):1725-31 [231022.001]
  • [Cites] Arch Ophthalmol. 1986 Jan;104(1):69-70 [2935125.001]
  • [Cites] Clin Exp Dermatol. 1986 Nov;11(6):624-7 [2959409.001]
  • [Cites] Leuk Res. 1989;13(4):339-43 [2523991.001]
  • [Cites] Cancer Res. 1989 Nov 1;49(21):6149-52 [2529028.001]
  • [Cites] J Natl Cancer Inst. 1990 Jun 20;82(12):1063 [2140863.001]
  • [Cites] Eur J Cancer. 1991;27(2):138-41 [1827276.001]
  • [Cites] J Clin Pharmacol. 1992 Dec;32(12):1089-95 [1487546.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):2036-42 [8410127.001]
  • [Cites] J Natl Cancer Inst. 1994 Jan 19;86(2):138-40 [8271297.001]
  • [Cites] J Cell Biochem Suppl. 1993;17G:226-33 [8007703.001]
  • [Cites] Curr Opin Cell Biol. 1994 Dec;6(6):825-31 [7880529.001]
  • [Cites] Am J Clin Oncol. 1997 Feb;20(1):36-9 [9020285.001]
  • [Cites] Tumori. 1997 Nov-Dec;83(6):884-94 [9526578.001]
  • [Cites] Arch Ophthalmol. 1998 Jun;116(6):759-63 [9639444.001]
  • [Cites] Clin Cancer Res. 1996 Dec;2(12):1931-5 [9816151.001]
  • [Cites] Mol Pharmacol. 1999 Mar;55(3):403-10 [10051523.001]
  • [Cites] J Natl Cancer Inst. 1999 Jul 7;91(13):1138-46 [10393722.001]
  • [Cites] Int J Oncol. 1999 Sep;15(3):499-504 [10427131.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2230-5 [10473110.001]
  • [Cites] J Neurosurg. 2001 Aug;95(2):190-8 [11780887.001]
  • [Cites] Cancer. 2000 Oct 1;89(7):1634-46 [11013380.001]
  • [Cites] Neurosurgery. 2000 Feb;46(2):419-30 [10690732.001]
  • [Cites] Drug Metab Dispos. 2000 Feb;28(2):205-8 [10640519.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2400-5 [12855611.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2032-9 [12796365.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Neuro Oncol. 2002 Oct;4(4):268-77 [12356357.001]
  • (PMID = 15514370.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062407; United States / NCI NIH HHS / CA / U01 CA062426; United States / NCRR NIH HHS / RR / M01 RR000079; United States / NCI NIH HHS / CA / R21 CA097767; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCRR NIH HHS / RR / M01-RR03186; United States / NCRR NIH HHS / RR / M01-RR0865; United States / NCRR NIH HHS / RR / M01 RR003186; United States / NCRR NIH HHS / RR / M01 RR000056; United States / NCRR NIH HHS / RR / M01-RR00079; United States / NCI NIH HHS / CA / U01CA62407-08; United States / NCI NIH HHS / CA / CA16672; United States / NCRR NIH HHS / RR / M01-RR00042; United States / NCRR NIH HHS / RR / M01 RR000865; United States / NCI NIH HHS / CA / U01CA62421; United States / NCI NIH HHS / CA / U01 CA062399; United States / NCRR NIH HHS / RR / M01-RR00056; United States / NCRR NIH HHS / RR / M01-RR00633; United States / NCRR NIH HHS / RR / M01 RR000633; United States / NCI NIH HHS / CA / U01 CA062405; United States / NCI NIH HHS / CA / U01 CA062412; United States / NCI NIH HHS / CA / CA62455; United States / NCI NIH HHS / CA / U01CA62399; United States / NCI NIH HHS / CA / CA62426; United States / NCI NIH HHS / CA / R21 CA097767-02; United States / NCI NIH HHS / CA / CA62422; United States / NCI NIH HHS / CA / U01 CA062421; United States / NCI NIH HHS / CA / CA097767-02; United States / NCRR NIH HHS / RR / M01 RR000042; United States / NCI NIH HHS / CA / U01CA62405; United States / NCI NIH HHS / CA / U01 CA062422; United States / NCI NIH HHS / CA / CA62399; United States / NCI NIH HHS / CA / CA62412
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 187EJ7QEXL / Fenretinide
  • [Other-IDs] NLM/ NIHMS278296; NLM/ PMC3820102
  •  go-up   go-down


9. Whelan JS, McTiernan A, Kakouri E, Kilby A, London Bone and Soft Tissue Tumour Service: Carboplatin-based chemotherapy for refractory and recurrent Ewing's tumours. Pediatr Blood Cancer; 2004 Sep;43(3):237-42
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carboplatin-based chemotherapy for refractory and recurrent Ewing's tumours.
  • BACKGROUND: Failure of first line therapy for the Ewing's family of tumours (EFT) is associated with a very poor outlook.
  • Studies of second line chemotherapy are therefore necessary to identify active agents and drug combinations.
  • Cisplatin-based therapy is frequently used in these circumstances but there are few studies to clearly define activity and toxicity.
  • PROCEDURE: Between 1990 and 1998, 23 males and 16 females aged between 6 and 48 years (median 23) with relapsed or refractory EFT were treated with carboplatin-based chemotherapy.
  • Previous chemotherapy had included ifosfamide and doxorubicin in all but two patients.
  • Twenty patients were treated at the time of recurrence, and 19 after a poor response to initial chemotherapy.
  • Treatment comprised of carboplatin to give an area under the plasma carboplatin concentration versus time curve of (AUC) 6 mg/ml, etoposide 120 mg/m2 for 3 days, and cyclophosphamide 500-750 mg/m2 for 2 days, repeated every 21 days.
  • Median time to progression was 10 weeks (range 2-54).
  • Six patients proceeded to high dose consolidation treatment with bone marrow or peripheral stem cell rescue.
  • [MeSH-major] Carboplatin / therapeutic use. Drug Resistance, Neoplasm. Sarcoma, Ewing / drug therapy. Sarcoma, Ewing / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Cohort Studies. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Prognosis. Recurrence. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 15266407.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin
  •  go-up   go-down


12. Basak GW, Urbanowska E, Boguradzki P, Torosian T, Halaburda K, Wiktor-Jedrzejczak W: Booster of plerixafor can be successfully used in addition to chemotherapy-based regimen to rescue stem cell mobilization failure. Ann Transplant; 2010 Oct-Dec;15(4):61-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Booster of plerixafor can be successfully used in addition to chemotherapy-based regimen to rescue stem cell mobilization failure.
  • BACKGROUND: Autologous stem cell transplantation (autoSCT) is currently considered one of the standard approaches in the treatment of patients suffering from multiple myeloma and recurrent or relapsed lymphomas.
  • Unfortunately, a significant proportion of those patients fail to mobilize minimum CD34+ cell dose to undergo this procedure.
  • Here we present the strategy that allows to rescue the outcome of ongoing unsuccessful chemotherapy based mobilizations.
  • CASE REPORT: All five patients failed to release satisfactory number of CD34+ cells to peripheral blood after chemotherapy plus G-CSF-based mobilization regimen, despite raise in leukocytosis.
  • Consequently, all five patients who would not otherwise collect required number of CD34+ cells, collected above 2.0×106 CD34+ cells/kg that allowed for hematopoietic stem cell transplantation.
  • CONCLUSIONS: We would like to suggest that poor mobilizers could be rescued with the timely addition of plerixafor, thus they can avoid another procedure of stem cell mobilization.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Mobilization / methods. Heterocyclic Compounds / therapeutic use. Salvage Therapy / methods
  • [MeSH-minor] Adult. Antigens, CD34. Female. Hematopoietic Stem Cell Transplantation. Humans. Male. Middle Aged. Receptors, CXCR3 / antagonists & inhibitors. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21183878.001).
  • [ISSN] 2329-0358
  • [Journal-full-title] Annals of transplantation
  • [ISO-abbreviation] Ann. Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Heterocyclic Compounds; 0 / Receptors, CXCR3; 155148-31-5 / JM 3100
  •  go-up   go-down


13. Stempak D, Gammon J, Halton J, Moghrabi A, Koren G, Baruchel S: A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors. J Pediatr Hematol Oncol; 2006 Nov;28(11):720-8
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors.
  • Tumor vasculature is a reasonable target for cancer therapy and lower more frequent doses of traditional chemotherapeutics [low-dose metronomic (LDM) chemotherapy] has been shown to have antiangiogenic efficacy.
  • This study evaluated the safety and pharmacokinetics of celecoxib and LDM vinblastine or cyclophosphamide in children with recurrent, refractory solid tumors.
  • We also investigated whether a subset of circulating plasma proteins are surrogate markers of angiogenic activity.
  • Celecoxib alone and with LDM chemotherapy was well tolerated and plasma concentrations were consistent with those shown to have antiangiogenic activity.
  • The surrogate markers measured (vascular endothelial growth factor, basic fibroblast growth factor, soluble vascular cell adhesion molecule, soluble intercellular cell adhesion molecule, endostatin, and thrombospondin-1) were highly variable and no statistically significant relationship between them and disease progression or maintenance of stable disease was observed.
  • We concluded that this regimen is well tolerated hence supporting the use of this form of therapy in pediatric patients.
  • However, future studies should include more homogenous patient populations and focus on validating surrogate markers to monitor treatment activity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Neoplasms / drug therapy. Pyrazoles / administration & dosage. Sulfonamides / administration & dosage. Vinblastine / administration & dosage
  • [MeSH-minor] Adolescent. Angiogenesis Inhibitors. Biomarkers / analysis. Celecoxib. Child. Child, Preschool. Drug Administration Schedule. Female. Humans. Male. Neoplasm Recurrence, Local. Pilot Projects

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • Hazardous Substances Data Bank. CELECOXIB .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17114958.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Biomarkers; 0 / Pyrazoles; 0 / Sulfonamides; 5V9KLZ54CY / Vinblastine; 8N3DW7272P / Cyclophosphamide; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


14. Mitina TA, Golenkov AK, Kataeva EV, Lutskaia TD, Trifonova EV, Klinushkina EF: [Effectiveness of bortezomib and bortezomib-containing programs for the treatment of recurrent and resistant multiple myeloma]. Ter Arkh; 2010;82(7):57-61
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effectiveness of bortezomib and bortezomib-containing programs for the treatment of recurrent and resistant multiple myeloma].
  • AIM: To evaluate the effectiveness of bortezomib and bortezomib-containing treatment programs in the therapy of resistant and recurrent multiple myeloma (MM) within a large unicenter study in real clinical practice conditions.
  • SUBJECTS AND METHODS: The study enrolled 101 patients (48 men and 53 women aged 34 to 77 years, mean age 54 years) with resistant and recurrent MM.
  • According to the types of paraprotein (PIg), the authors revealed the usual distribution: G, 60.7%; A, 23.8%; BJ, 13%; M, 1.15%; D, 1.15%.
  • The patients were randomized into 4 treatment groups: V1--velcade 1.3 mg/m2 intravenously on days 1, 4, 8, and 11 of a 21-day cycle; V2--velcade 1.3 mg/m2 intravenously on days 1, 4, 8, and 11, melphalan 20 mg orally on day 2 of a 28-day cycle; V3--velcade 1.3 mg/m2 intravenously on days 1, 4, 8, and 11, melphalan 9 mg/m2 orally for 4 days, prednisolone 60 mg/m2 orally for 4 days of a 42-day cycle; V4--velcade 1.3 mg/m2 intravenously on days 1, 4, 8, and 11, melphalan 9 mg/m2 orally for 4 days, prednisolone 60 mg/m2 orally for 4 days, cyclophosphanum, 250 mg/m2 intravenously dropwise on days 1 to 7 of a 60-day cycle.
  • An average of 6.5 induction treatment cycles was performed.
  • RESULTS: Amongst the 27 patients receiving bortezomib therapy (V1), an objective response to therapy was obtained in 70.3%, including a complete response (CR) in 18.5%, a near-complete response (NCR) in 14.8%, and a partial response (PR) in 37%.
  • CONCLUSION: Bortezomib in the monotherapy and multidrug therapy for resistant and recurrent MM shows immediate and long-term benefits and a low toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Multiple Myeloma / drug therapy
  • [MeSH-minor] Adult. Aged. Boronic Acids / administration & dosage. Boronic Acids / adverse effects. Boronic Acids / therapeutic use. Bortezomib. Disease-Free Survival. Drug Resistance, Neoplasm / drug effects. Female. Humans. Male. Middle Aged. Pyrazines / administration & dosage. Pyrazines / adverse effects. Pyrazines / therapeutic use. Secondary Prevention

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20853611.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


15. Ria R, Di Ianni M, Sportoletti P, Cimminiello M, Marcomigni L, Tabilio A: Recurrent primary plasmacytoma of the eyelid with rapid regional metastasis. Leuk Lymphoma; 2006 Mar;47(3):549-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent primary plasmacytoma of the eyelid with rapid regional metastasis.
  • No plasma cell infiltration was observed at bone marrow biopsy.
  • Histology and immunohistochemistry confirmed plasma cell infiltration.
  • Tumor cell clonality was determined by immunohistological staining; cells were positive for kappa light chain like the first eyelid tumor.
  • Twenty months later, biopsy of one enlarged right cervical lymph node showed massive diffuse infiltration of atypical plasma cells (CD20(-), CD79a(+), CD138(+), MUM1/IRF4(+)).
  • No adjuvant chemotherapy was given.
  • No plasma cell infiltration was observed at bone marrow biopsy.
  • As this case might be a particularly slow-progressing extra-medullary plasmacytoma, this study recommends closely monitored follow-ups so that the aggressive form can be treated in time.
  • [MeSH-major] Eyelid Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Plasmacytoma / pathology
  • [MeSH-minor] Adult. Biopsy. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Remission Induction. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16396779.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


16. Schneider BJ, Worden FP, Gadgeel SM, Parchment RE, Hodges CM, Zwiebel J, Dunn RL, Wozniak AJ, Kraut MJ, Kalemkerian GP: Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer. Invest New Drugs; 2009 Dec;27(6):571-8
Hazardous Substances Data Bank. VITAMIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer.
  • BACKGROUND: Alterations in retinoid signaling appear to be involved in the pathogenesis of small cell lung cancer (SCLC).
  • Since these data suggested that SCLC is the adult solid tumor that is most susceptible to fenretinide, a trial to evaluate the clinical activity of fenretinide in patients with SCLC was considered the definitive test of its clinical potential in adult oncology.
  • METHODS: Patients with progressive SCLC after one or two prior chemotherapy regimens and a performance status of 0-2 were eligible for the study.
  • Blood and saliva were collected pre-treatment and on day 7 of cycle 1 to measure fenretinide and retinol levels by high-pressure liquid chromatography (HPLC).
  • Fifteen patients had one prior chemotherapy regimen and four patients had two prior regimens.
  • The median time from diagnosis to enrollment was 10 months.
  • The median time to treatment failure was 5.7 weeks overall, while the four patients with stable disease demonstrated treatment failure at 11, 13, 19, and 52 weeks.
  • Median survival was 25 weeks, with one patient alive 22 months after the start of treatment.
  • The mean day 7 plasma fenretinide level was 2.90 +/- 1.66 μg/ml (7.40 +/- 4.25 muM; n = 14).
  • The mean pre-treatment and day 7 plasma retinol levels were 0.47 +/- 0.16 μg/ml and 0.05 +/- 0.07 μg/ml (n = 8), respectively.
  • The mean day 7 salivary fenretinide level was 0.08 +/- 0.18 μg/ml, with no correlation between salivary and plasma drug levels.
  • Plasma concentrations of fenretinide that induce cytotoxicity in vitro in SCLC cell lines are clinically achievable, but there were no objective responses.
  • Non-invasive drug monitoring using saliva underestimates systemic exposure.
  • [MeSH-major] Fenretinide / therapeutic use. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Small Cell Lung Carcinoma / drug therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Dose-Response Relationship, Drug. Female. Humans. Male. Middle Aged. Survival Analysis. Time Factors. Treatment Outcome. Vitamin A / therapeutic use

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 May 15;59(10):2493-8 [10344763.001]
  • [Cites] J Biol Chem. 2002 Dec 20;277(51):49531-7 [12388538.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] J Cell Biochem Suppl. 1995;23:80-6 [8747381.001]
  • [Cites] Invest New Drugs. 2005 Mar;23(2):179-85 [15744595.001]
  • [Cites] Cancer Res. 1989 Nov 1;49(21):6149-52 [2529028.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4606-13 [14555536.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Cancer Treat Rep. 1987 Apr;71(4):391-405 [3548957.001]
  • [Cites] Cancer Res. 1993 Dec 15;53(24):6036-41 [8261419.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):2036-42 [8410127.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2032-9 [12796365.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1664-70 [11250995.001]
  • [Cites] Exp Cell Res. 1991 Jul;195(1):163-70 [1675998.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1345-55 [9607596.001]
  • [Cites] J Clin Oncol. 2004 Nov 1;22(21):4282-9 [15514370.001]
  • [Cites] Apoptosis. 2006 Oct;11(10):1677-94 [16850162.001]
  • [Cites] Leukemia. 2002 May;16(5):902-10 [11986953.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1794-801 [10561217.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):658-67 [10080612.001]
  • [Cites] J Natl Cancer Inst. 1995 Nov 15;87(22):1674-80 [7473815.001]
  • [Cites] J Natl Cancer Inst. 1994 Aug 17;86(16):1245-7 [8040893.001]
  • [Cites] Cancer Res. 1995 Dec 1;55(23):5603-10 [7585641.001]
  • [Cites] N Engl J Med. 2004 Jan 22;350(4):379-92 [14736930.001]
  • [Cites] J Natl Cancer Inst. 1985 Nov;75(5):871-5 [2932587.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1914-9 [17035399.001]
  • [Cites] Int J Oncol. 1995 Sep;7(3):433-41 [21552857.001]
  • [Cites] J Natl Cancer Inst. 2004 Sep 1;96(17):1264-5 [15339958.001]
  • [Cites] Adv Pharmacol. 1995;33:315-47 [7495674.001]
  • [Cites] Cell Growth Differ. 1993 Oct;4(10):799-809 [8274449.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;43(2):145-50 [9923820.001]
  • [Cites] Oncogene. 1991 Oct;6(10):1859-68 [1717924.001]
  • [Cites] J Natl Compr Canc Netw. 2008 Mar;6(3):323-31 [18377850.001]
  • (PMID = 19225720.001).
  • [ISSN] 1573-0646
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 11103-57-4 / Vitamin A; 187EJ7QEXL / Fenretinide
  •  go-up   go-down


17. Gilaberte M, Gallardo F, Bellosillo B, Saballs P, Barranco C, Serrano S, Pujol RM: Recurrent and self-healing cutaneous monoclonal plasmablastic infiltrates in a patient with AIDS and Kaposi sarcoma. Br J Dermatol; 2005 Oct;153(4):828-32
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent and self-healing cutaneous monoclonal plasmablastic infiltrates in a patient with AIDS and Kaposi sarcoma.
  • Plasmablastic lymphoma (PBL) is a rare variant of diffuse large cell lymphoma that often involves the oral cavity of HIV+ patients.
  • It is characterized by immunoblastic morphology and plasma cell phenotype.
  • We report a 44-year-old man with AIDS and Kaposi sarcoma (KS) previously treated with doxorubicin who, following treatment with highly active antiretroviral therapy, developed an erythematous infiltrated nodule on the right arm.
  • Histology showed subcutaneous fat necrosis and clusters of atypical large plasma cells (plasmablastic cells).
  • Two years later an infiltrated plaque developed on the abdominal wall.
  • PBL may be seen in patients with transplants or receiving chemotherapy, but is usually observed in patients with advanced AIDS.
  • The observation of recurrent self-healing EBV- and HHV-8-associated cutaneous monoclonal plasmablastic infiltrates, in a patient with AIDS and KS, expands the clinical spectrum of AIDS-associated plasmablastic lymphoproliferative disorders.
  • [MeSH-minor] Adult. Humans. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / virology. Male. Neoplasm Regression, Spontaneous. Recurrence

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16181470.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


18. Armstrong DK, Fleming GF, Markman M, Bailey HH: A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol; 2006 Nov;103(2):391-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study.
  • METHODS: Twelve patients with recurrent or persistent ovarian or primary peritoneal carcinoma were treated.
  • Treatment could be repeated once, 8 weeks after initial treatment.
  • RESULTS: One dose-limiting toxicity consisting of abdominal pain, ileus and bowel obstruction was seen with the second cycle of therapy in one patient who received 900 mg/m2.
  • The study was discontinued before MTD was defined due to the manufacturer's decision to suspend further clinical development of paclitaxel microspheres.
  • Pharmacokinetic analysis showed a trend toward a dose-dependent effect of IP paclitaxel microspheres on measured plasma paclitaxel levels.
  • Sustained paclitaxel levels were maintained throughout all 8 weeks of therapy; however, paclitaxel concentrations were well below the plasma concentrations associated with toxicity.
  • In one patient, laparoscopy revealed extensive adhesions, fat necrosis, foreign body giant cell reaction and detectable residual polymer filaments 7 months after completion of treatment with paclitaxel microspheres.
  • The low but persistent detection of plasma paclitaxel indicates that paclitaxel continues to be released for at least 8 weeks after IP paclitaxel microsphere treatment.
  • The finding of significant peritoneal abnormalities, including the presence of residual polymer filaments, months after IP Paclimer treatment suggests that the polymer preparation used in Paclimer degrades slowly.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / adverse effects. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy. Paclitaxel / administration & dosage. Paclitaxel / adverse effects

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16626792.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Delayed-Action Preparations; 0 / polilactofate; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


19. Antoniou D, Pavlakou G, Stathopoulos GP, Karydis I, Chondrou E, Papageorgiou C, Dariotaki F, Chaimala D, Veslemes M: Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer. Lung Cancer; 2006 Aug;53(2):205-10
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer.
  • Patients with cancer may present with one or more circulatory markers of haemostatic activation which may be associated with tumor growth and cancer cell dissemination.
  • The aim of the present study was to detect the D-dimer plasma levels in advanced-stage lung cancer patients before, during and after chemotherapy, and to determine whether there is a correlation with response rate, disease recurrence and survival, in order to estimate the possible predictive value of D-dimer plasma levels.
  • Forty-seven/52 patients were evaluable and analysed; 38 patients had non-small-cell lung cancer (NSCLC) and 9 small-cell lung cancer (SCLC) and all were at an advanced stage or inoperable.
  • We found that 14/19 (73.7%) patients with CR or PR showed a reduction in D-dimer plasma values and 11/16 (68.8%) with PD showed increased values; also, in patients with recurrent disease (12/13, 92.3%), D-dimer plasma levels were increased.
  • D-Dimer plasma levels decrease or increase after response and progressive disease, respectively, and can act as a predictive factor of the evolution of the disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Carcinoma, Non-Small-Cell Lung / blood. Carcinoma, Small Cell / blood. Fibrin Fibrinogen Degradation Products / metabolism. Lung Neoplasms / blood
  • [MeSH-minor] Adult. Aged. Bridged Compounds / administration & dosage. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Paclitaxel / administration & dosage. Patient Compliance. Predictive Value of Tests. Prospective Studies. Survival Analysis. Taxoids / administration & dosage. Treatment Outcome. Vinblastine / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16769149.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Bridged Compounds; 0 / Fibrin Fibrinogen Degradation Products; 0 / Taxoids; 0 / fibrin fragment D; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 1605-68-1 / taxane; 5V9KLZ54CY / Vinblastine; 7673326042 / irinotecan; B76N6SBZ8R / gemcitabine; P88XT4IS4D / Paclitaxel; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


20. Han ES, Burger RA, Darcy KM, Sill MW, Randall LM, Chase D, Parmakhtiar B, Monk BJ, Greer BE, Connelly P, Degeest K, Fruehauf JP: Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer. Gynecol Oncol; 2010 Dec;119(3):484-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer.
  • METHODS: Recurrent/persistent EOC/PPC patients were treated with bevacizumab (15 mg/kg IV q21days) until disease progression.
  • Pre-cycle 1/4 serum and plasma VEGF were quantified using a validated-ELISA.
  • IHC and plasma biomarkers did not change with bevacizumab treatment except for serum VEGF, which appeared to decrease during bevacizumab treatment.
  • CONCLUSIONS: Despite the limitations in sample size and exploratory nature of the study, angiogenic markers in tumor and serum may provide prognostic value in recurrent/persistent EOC/PPC, and are being prospectively evaluated in the GOG phase III trial of carboplatin, paclitaxel and bevacizumab/placebo in previously untreated EOC/PPC.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [Cites] Cancer Res. 2000 Jun 1;60(11):2898-905 [10850435.001]
  • [Cites] Biometrika. 1945 Nov;33:239-51 [21006841.001]
  • [Cites] FASEB J. 2000 Sep;14(12):1674-6 [10973914.001]
  • [Cites] Clin Cancer Res. 2001 Jan;7(1):81-8 [11205922.001]
  • [Cites] Gynecol Oncol. 2001 Aug;82(2):273-8 [11531279.001]
  • [Cites] Gynecol Oncol. 2002 Jul;86(1):85-90 [12079305.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3814-25 [14551300.001]
  • [Cites] Gynecol Oncol. 2004 Nov;95(2):323-9 [15491752.001]
  • [Cites] Int J Cancer. 1994 Oct 15;59(2):191-5 [7927918.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6504-11 [7527299.001]
  • [Cites] Am J Pathol. 1995 Jul;147(1):33-41 [7541612.001]
  • [Cites] J Surg Res. 1996 Jun;63(1):39-43 [8661169.001]
  • [Cites] Br J Cancer. 1998 Mar;77(6):956-64 [9528841.001]
  • [Cites] Cancer Detect Prev. 1998;22(3):185-94 [9618039.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):587-91 [10100710.001]
  • [Cites] Circulation. 1999 Sep 28;100(13):1423-31 [10500044.001]
  • [Cites] Histopathology. 2005 May;46(5):481-9 [15842629.001]
  • [Cites] Surgeon. 2005 Jun;3(3):197-205 [16076005.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):217-27 [16365183.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):769-77 [16391297.001]
  • [Cites] Nat Rev Cancer. 2006 Aug;6(8):626-35 [16837971.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5018-22 [16951216.001]
  • [Cites] Gynecol Oncol. 2007 Feb;104(2):345-51 [17027070.001]
  • [Cites] J Clin Oncol. 2007 May 1;25(13):1816-8 [17470880.001]
  • [Cites] Gynecol Oncol. 2007 Jul;106(1):221-32 [17481705.001]
  • [Cites] J Clin Oncol. 2007 Nov 20;25(33):5165-71 [18024863.001]
  • [Cites] J Clin Oncol. 2007 Nov 20;25(33):5180-6 [18024865.001]
  • [Cites] J Clin Oncol. 2008 Jan 1;26(1):76-82 [18165643.001]
  • [Cites] Cell Mol Life Sci. 2008 Mar;65(5):700-12 [18193162.001]
  • [Cites] Clin Cancer Res. 2008 May 15;14(10):3030-5 [18483368.001]
  • [Cites] Gynecol Oncol. 2008 Dec;111(3):487-95 [18834621.001]
  • [Cites] Gynecol Oncol. 2009 Mar;112(3):469-74 [19135712.001]
  • [Cites] Cancer Cell. 2009 Mar 3;15(3):167-70 [19249675.001]
  • [Cites] Cancer Cell. 2009 Mar 3;15(3):220-31 [19249680.001]
  • [Cites] Cancer Cell. 2009 Mar 3;15(3):232-9 [19249681.001]
  • [Cites] Ann N Y Acad Sci. 2000 Jun;910:121-37; discussion 137-9 [10911910.001]
  • (PMID = 20870280.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA062203-14S25594; United States / NCI NIH HHS / CA / CA062203-14S25594; United States / NCI NIH HHS / CA / P30 CA062203-099016; United States / NCI NIH HHS / CA / CA 11479; United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / U10 CA027469; United States / NCI NIH HHS / CA / CA 27269; United States / NCI NIH HHS / CA / R43 CA097900-01; United States / NCI NIH HHS / CA / CA097900-01; United States / NCI NIH HHS / CA / CA062203-099016; United States / NCI NIH HHS / CA / U10 CA037517; United States / NCI NIH HHS / CA / R43 CA097900; United States / NCI NIH HHS / CA / CA 37517; United States / NCI NIH HHS / CA / P30 CA062203
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD31; 0 / TP53 protein, human; 0 / Thrombospondin 1; 0 / Tumor Suppressor Protein p53; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  • [Other-IDs] NLM/ NIHMS240926; NLM/ PMC2975758
  •  go-up   go-down


21. Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK: Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol; 2010 Jun 10;28(17):2817-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
  • We performed a phase II study of cediranib in patients with recurrent glioblastoma.
  • METHODS: Cediranib, an oral pan-VEGF receptor tyrosine kinase inhibitor, was administered (45 mg/d) until progression or unacceptable toxicity to patients with recurrent glioblastoma.
  • We performed magnetic resonance imaging (MRI) and plasma and urinary biomarker evaluations at multiple time points.
  • RESULTS: Thirty-one patients with recurrent glioblastoma were accrued.
  • Fifteen (48.4%) of 31 patients required at least one dose reduction and 15 patients required temporary drug interruptions due to toxicity.
  • Drug interruptions were not associated with outcome.
  • Changes in plasma placental growth factor, basic fibroblast growth factor, matrix metalloproteinase (MMP) -2, soluble VEGF receptor 1, stromal cell-derived factor-1alpha, and soluble Tek/Tie2 receptor and in urinary MMP-9/neutrophil gelatinase-associated lipocalin activity after cediranib were associated with radiographic response or survival.
  • CONCLUSION: Cediranib monotherapy for recurrent glioblastoma is associated with encouraging proportions of radiographic response, 6-month progression-free survival, and a steroid-sparing effect with manageable toxicity.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Quinazolines / therapeutic use. Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / blood. Disease-Free Survival. Female. Humans. Male. Middle Aged. Protein Kinase Inhibitors / adverse effects. Protein Kinase Inhibitors / therapeutic use. Young Adult

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1994 Feb 10;367(6463):576-9 [8107827.001]
  • [Cites] Neuro Oncol. 2010 May;12(5):466-72 [20406897.001]
  • [Cites] Cancer Res. 1995 Mar 1;55(5):1189-93 [7532545.001]
  • [Cites] Exp Toxicol Pathol. 1995 May;47(2-3):89-94 [7580112.001]
  • [Cites] Int J Cancer. 1999 Feb 19;84(1):10-8 [9988225.001]
  • [Cites] Science. 1999 Jun 18;284(5422):1994-8 [10373119.001]
  • [Cites] Cancer Cell. 2004 Dec;6(6):553-63 [15607960.001]
  • [Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]
  • [Cites] Ann Oncol. 2005 Apr;16(4):558-65 [15705616.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4389-400 [15899831.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):16-24 [16330672.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):217-27 [16365183.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):843-5 [1279431.001]
  • [Cites] J Nucl Med. 1992 Dec;33(12):2133-7 [1334136.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Jan;3(1):24-40 [16407877.001]
  • [Cites] Neuro Oncol. 2007 Jan;9(1):29-38 [17108063.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Nat Protoc. 2007;2(4):805-10 [17446880.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2643-50 [17473195.001]
  • [Cites] Neurosurgery. 2007 Jun;60(6):E1148-9; discussion E1149 [17538362.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3045-54 [17634482.001]
  • [Cites] Nat Rev Neurosci. 2007 Aug;8(8):610-22 [17643088.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1407-12 [18316562.001]
  • [Cites] J Clin Oncol. 2008 Apr 10;26(11):1810-6 [18347007.001]
  • [Cites] Clin Cancer Res. 2008 Apr 15;14(8):2378-86 [18413828.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14(20):6610-7 [18927302.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Nov;5(11):634-44 [18711427.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):740-5 [19114704.001]
  • [Cites] Cancer Cell. 2009 Mar 3;15(3):220-31 [19249680.001]
  • [Cites] Cancer Cell. 2009 Mar 3;15(3):232-9 [19249681.001]
  • [Cites] J Clin Oncol. 2009 May 20;27(15):2542-52 [19332720.001]
  • [Cites] Nat Rev Clin Oncol. 2009 Jun;6(6):327-38 [19483739.001]
  • [Cites] J Clin Oncol. 2009 Jun 20;27(18):3027-35 [19470923.001]
  • [Cites] Cancer Res. 2009 Jul 1;69(13):5296-300 [19549889.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4733-40 [19720927.001]
  • [Cites] Cancer Res. 2009 Oct 15;69(20):7905-10 [19826039.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jun 15;29(3):427-31 [8005794.001]
  • (PMID = 20458050.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00305656
  • [Grant] United States / NCI NIH HHS / CA / P01-CA455481; United States / NCRR NIH HHS / RR / P41-RR014075; United States / NCI NIH HHS / CA / R21 CA117079; United States / NCI NIH HHS / CA / R01 CA129371; United States / NCRR NIH HHS / RR / P41 RR014075; United States / NCI NIH HHS / CA / K24 CA125440; United States / NCI NIH HHS / CA / R01-CA118764; United States / NCI NIH HHS / CA / R01-CA115767; United States / NCI NIH HHS / CA / P01-CA80124; United States / NCI NIH HHS / CA / R01 CA118764; United States / NCRR NIH HHS / RR / M01 RR001066; United States / NCRR NIH HHS / RR / 1UL1RR025758-01; United States / NCI NIH HHS / CA / P01 CA080124; United States / NCI NIH HHS / CA / R01-CA129371; United States / NCI NIH HHS / CA / K24-CA125440; United States / NCRR NIH HHS / RR / UL1 RR025758; United States / NCRR NIH HHS / RR / M01-RR-01066; United States / NCI NIH HHS / CA / R01 CA115767; United States / NCI NIH HHS / CA / R21-CA117079
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor; NQU9IPY4K9 / cediranib
  • [Other-IDs] NLM/ PMC2903316
  •  go-up   go-down


22. Fountzilas G, Fragkoulidi A, Kalogera-Fountzila A, Nikolaidou M, Bobos M, Calderaro J, Andreiuolo F, Marselos M: A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer. Cancer Chemother Pharmacol; 2010 Mar;65(4):649-60
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer.
  • PURPOSE: Patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN) bear a grave prognosis.
  • We, therefore, evaluated the activity and safety of sunitinib, an oral tyrosine kinase inhibitor that targets multiple receptors, in patients with RM-SCCHN.
  • Sunitinib and SU012662 plasma levels were determined based on a validated liquid chromatography-tandem mass spectrometry method and pharmacokinetic data were fitted in a non-compartmental analysis.
  • RESULTS: Totally, 28 6-week cycles of treatment with sunitinib were administered (median, 2 cycles).
  • Mean maximum concentrations (C(max)) were reached during the first day of treatment for sunitinib at 38.98 (+ or - 22.66) ng/ml and for SU012662 at 11.12 (+ or - 24.57) ng/ml.
  • Our results showed that SU012662 has a longer half-life and a larger volume of distribution than the parent drug sunitinib.
  • CONCLUSIONS: According to our findings, sunitinib monotherapy was not proven active in RM-SCCHN, and no further development of the drug in this indication is warranted.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Indoles / therapeutic use. Pyrroles / therapeutic use
  • [MeSH-minor] Aged. Anorexia / chemically induced. Area Under Curve. Drug Administration Schedule. Fatigue / chemically induced. Female. Humans. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Immunohistochemistry. Male. Metabolic Clearance Rate. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Survival Analysis. Thrombocytopenia / chemically induced. Treatment Outcome. Vascular Endothelial Growth Factor A / metabolism

  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19655144.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Indoles; 0 / Pyrroles; 0 / SU 12662; 0 / Vascular Endothelial Growth Factor A; 0 / sunitinib
  •  go-up   go-down


23. Knox JJ, Siu LL, Chen E, Dimitroulakos J, Kamel-Reid S, Moore MJ, Chin S, Irish J, LaFramboise S, Oza AM: A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. Eur J Cancer; 2005 Mar;41(4):523-30
Hazardous Substances Data Bank. LOVASTATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix.
  • Squamous cell carcinomas of the head and neck (HNSCC) and of the cervix (CC) are particularly sensitive to the apoptotic effects of lovastatin in vitro.
  • Plasma samples were collected for pharmacokinetic analysis.
  • Biologically relevant plasma lovastatin levels were obtained.
  • One patient achieved SD and clinical benefit for 14 months on study and a further 23 months off treatment.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage. Lovastatin / administration & dosage. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Statins.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15737556.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 9LHU78OQFD / Lovastatin
  •  go-up   go-down


24. Grossman SA, Alavi JB, Supko JG, Carson KA, Priet R, Dorr FA, Grundy JS, Holmlund JT: Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas. Neuro Oncol; 2005 Jan;7(1):32-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas.
  • Protein kinase C alpha (PKC-alpha) is a cytoplasmic serine threonine kinase involved in regulating cell differentiation and proliferation.
  • Aprinocarsen is an antisense oligonucleotide against PKC-alpha that reduces PKC-alphain human cell lines and inhibits a human glioblastoma tumor cell line in athymic mice.
  • In this phase 2 study, aprinocarsen was administered to patients with recurrent high-grade gliomas by continuous intravenous infusion (2.0 mg/kg/day for 21 days per month).
  • The number of prior chemotherapy regimens included none (n = 3), one (n = 10), and two (n = 8).
  • Patients on this therapy rapidly developed symptoms of increased intracranial pressure with increased edema, enhancement, and mass effect on neuroimaging.
  • The median time to progression was 36 days, and median survival was 3.4 months.
  • The observed toxicities were mild, reversible, and uncommon (grade 3 thrombocytopenia [n = 3] and grade 4 AST [n = 1]), and no coagulopathy or CNS bleeding resulted from this therapy.
  • Plasma concentrations of aprinocarsen during the infusion exhibited significant interpatient variability (mean = 1.06 mug/ml; range, 0.34-6.08 mug/ml).

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Pharmacol. 1996 Aug;50(2):236-42 [8700129.001]
  • [Cites] Glia. 1999 Feb 1;25(3):240-6 [9932870.001]
  • [Cites] J Biopharm Stat. 1997 Mar;7(1):171-8 [9056596.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3121-8 [9294475.001]
  • [Cites] J Biol Chem. 1998 Mar 13;273(11):6001-4 [9497312.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3586-95 [10550158.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3357-63 [10589745.001]
  • [Cites] Prog Neurobiol. 2001 Feb;63(3):321-36 [11115728.001]
  • [Cites] Curr Oncol Rep. 2000 Sep;2(5):445-53 [11122877.001]
  • [Cites] Neurosci Lett. 2001 Jan 19;297(3):163-6 [11137753.001]
  • [Cites] Brain Res Mol Brain Res. 2001 Nov 1;95(1-2):110-6 [11687282.001]
  • [Cites] Curr Oncol Rep. 2002 Jan;4(1):37-46 [11734112.001]
  • [Cites] Expert Opin Investig Drugs. 2001 Dec;10(12):2117-40 [11772309.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2002 Feb;72(2):262-5 [11796780.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1042-8 [11948111.001]
  • [Cites] Neurosci Lett. 2002 May 17;324(2):105-8 [11988338.001]
  • [Cites] Am J Physiol Renal Physiol. 2002 Aug;283(2):F309-18 [12110515.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2188-92 [12114419.001]
  • [Cites] J Anat. 2002 Jun;200(6):617-27 [12162729.001]
  • [Cites] J Anat. 2002 Jun;200(6):639-46 [12162731.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):96-103 [12672281.001]
  • [Cites] Lancet Neurol. 2003 Jul;2(7):404-9 [12849118.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2940-9 [12912940.001]
  • [Cites] J Pharm Sci. 1985 Feb;74(2):229-31 [3989700.001]
  • [Cites] Chem Pharm Bull (Tokyo). 1985 Apr;33(4):1620-32 [4042238.001]
  • [Cites] Biochem Biophys Res Commun. 1987 Oct 29;148(2):718-25 [3689368.001]
  • [Cites] Nature. 1988 Aug 25;334(6184):661-5 [3045562.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Cancer Res. 1989 Jun 15;49(12):3215-7 [2720675.001]
  • [Cites] Biochem Biophys Res Commun. 1989 Sep 29;163(3):1377-83 [2783141.001]
  • [Cites] Cancer Res. 1990 Feb 1;50(3):677-85 [2297708.001]
  • [Cites] Br J Cancer. 1992 Jul;66(1):10-9 [1637658.001]
  • [Cites] Pharmacol Ther. 1993 Sep;59(3):257-80 [8309991.001]
  • [Cites] J Biol Chem. 1994 Jun 10;269(23):16416-24 [7911467.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11762-6 [7972137.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;42(2):118-26 [9654111.001]
  • [Cites] Anal Biochem. 1996 Mar 1;235(1):36-43 [8850544.001]
  • (PMID = 15701280.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062475; United States / NCI NIH HHS / CA / U01-CA-26406; United States / NCI NIH HHS / CA / UO1CA-62475
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Oligonucleotides, Antisense; 0 / Phosphorothioate Oligonucleotides; EC 2.7.11.13 / PRKCA protein, human; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.13 / Protein Kinase C-alpha; FMT95051CQ / aprinocarsen
  • [Other-IDs] NLM/ PMC1871621
  •  go-up   go-down


25. Fang F, Balch C, Schilder J, Breen T, Zhang S, Shen C, Li L, Kulesavage C, Snyder AJ, Nephew KP, Matei DE: A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer; 2010 Sep 1;116(17):4043-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer.
  • On the basis of preclinical studies indicating that hypomethylating agents can reverse platinum resistance in ovarian cancer cells, the authors conducted a phase 1 trial of low-dose decitabine combined with carboplatin in patients with recurrent, platinum-resistant ovarian cancer.
  • Peripheral blood mononuclear cells (PBMCs) and plasma collected on Days 1 (pretreatment), 5, 8, and 15 were used to assess global (LINE-1 repetitive element) and gene-specific DNA methylation.
  • Of 5 ovarian cancer-associated methylated genes, HOXA11 and BRCA1 were demethylated in plasma on Days 8 and 15.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • Hazardous Substances Data Bank. AZACITIDINE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Invest New Drugs. 2000 Feb;18(1):83-91 [10830142.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3410-8 [11309301.001]
  • [Cites] Oncology. 2001;61(2):129-33 [11528251.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2246-52 [12114427.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1186-93 [12142371.001]
  • [Cites] Br J Cancer. 2002 Oct 7;87(8):815-24 [12373593.001]
  • [Cites] Am J Clin Oncol. 2002 Oct;25(5):496-501 [12393992.001]
  • [Cites] Nat Rev Cancer. 2003 Jul;3(7):502-16 [12835670.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5511-7 [15289362.001]
  • [Cites] Oncogene. 2004 Sep 2;23(40):6779-87 [15273730.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6476-81 [15374957.001]
  • [Cites] Gynecol Oncol. 2004 Nov;95(2):370-6 [15491759.001]
  • [Cites] Cancer Res. 1990 Aug 1;50(15):4572-7 [1695122.001]
  • [Cites] Leukemia. 1997 Mar;11 Suppl 1:S24-7 [9130688.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):67-70 [9892187.001]
  • [Cites] Am J Obstet Gynecol. 2004 Nov;191(5):1552-72 [15547525.001]
  • [Cites] Front Biosci. 2005;10:1897-931 [15769674.001]
  • [Cites] N Engl J Med. 2005 Mar 24;352(12):1268-9; author reply 1268-9 [15791705.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):275-84 [15803154.001]
  • [Cites] Int J Gynecol Cancer. 2005 Sep-Oct;15(5):679-91 [16174214.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8961-7 [16204069.001]
  • [Cites] Mol Cancer Ther. 2005 Oct;4(10):1505-14 [16227399.001]
  • [Cites] J Natl Cancer Inst. 2005 Oct 19;97(20):1498-506 [16234563.001]
  • [Cites] Nucleic Acids Res. 2005;33(21):6823-36 [16326863.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9351-8 [16361635.001]
  • [Cites] BMC Cancer. 2006;6:201 [16879751.001]
  • [Cites] N Engl J Med. 2006 Sep 21;355(12):1253-61 [16990388.001]
  • [Cites] Clin Cancer Res. 2006 Dec 15;12(24):7347-52 [17189406.001]
  • [Cites] Blood. 2007 Jan 1;109(1):52-7 [16882708.001]
  • [Cites] Cell. 2007 Feb 23;128(4):683-92 [17320506.001]
  • [Cites] Front Biosci. 2007;12:4254-66 [17485372.001]
  • [Cites] Semin Oncol. 2007 Apr;34(2 Suppl 2):S1-15 [17512352.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jul;63(1):12-31 [17336087.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4519-21 [17925545.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4603-9 [17925555.001]
  • [Cites] Blood. 2008 Feb 15;111(4):2382-4 [18055864.001]
  • [Cites] Gynecol Oncol. 2008 Apr;109(1):129-39 [18234305.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):8-13 [18425818.001]
  • [Cites] Cancer. 2008 Jun;112(11):2341-51 [18398832.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4311-20 [18519691.001]
  • [Cites] Int J Cancer. 2008 Aug 1;123(3):725-9 [18478570.001]
  • [Cites] Int J Gynecol Cancer. 2008 Jul-Aug;18(4):615-20 [18754135.001]
  • [Cites] Curr Probl Cancer. 2008 Sep-Oct;32(5):187-235 [18926282.001]
  • [Cites] Int J Cancer. 2009 Jan 15;124(2):387-93 [18942711.001]
  • [Cites] Am J Obstet Gynecol. 2009 Feb;200(2):177.e1-9 [19110234.001]
  • [Cites] Nat Rev Cancer. 2009 Mar;9(3):167-81 [19238149.001]
  • [Cites] J Biopharm Stat. 2009;19(3):543-55 [19384695.001]
  • [Cites] Mol Cancer. 2009;8:48 [19602291.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):6039-44 [11085525.001]
  • (PMID = 20564122.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA13387701; United States / NCI NIH HHS / CA / CA113001-02; United States / NCI NIH HHS / CA / R01 CA085289; United States / NCI NIH HHS / CA / R01 CA085289-06; United States / NCI NIH HHS / CA / R21 CA133877; United States / NCI NIH HHS / CA / CA085289; United States / NCI NIH HHS / CA / U54 CA113001; United States / NCI NIH HHS / CA / R21 CA133877-02; United States / NCI NIH HHS / CA / CA113001; United States / NCI NIH HHS / CA / CA133877-02; United States / NCI NIH HHS / CA / CA085289-06; United States / NCI NIH HHS / CA / U54 CA113001-02
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Platinum Compounds; 776B62CQ27 / decitabine; BG3F62OND5 / Carboplatin; M801H13NRU / Azacitidine
  • [Other-IDs] NLM/ NIHMS189740; NLM/ PMC2930033
  •  go-up   go-down


26. Schilder RJ, Sill MW, Lee RB, Shaw TJ, Senterman MK, Klein-Szanto AJ, Miner Z, Vanderhyden BC: Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol; 2008 Jul 10;26(20):3418-25
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study.
  • PURPOSE: This phase II trial assessed the activity and tolerability of an oral dose of imatinib mesylate 400 mg twice daily in patients with recurrent or persistent epithelial ovarian or primary peritoneal carcinoma.
  • Mutational analysis of KIT, immunohistochemistry (IHC) and enzyme-linked immunosorbent assay for markers (KIT, platelet-derived growth factor [PDGF] receptor [-R], AKT2, phosphorylated AKT [p-AKT], stem cell factor [SCF], and PDGF) were performed.
  • Higher pretreatment plasma concentrations of PDGF-AB, PDGF-BB, and vascular endothelial growth factor (VEGF) were individually associated with shorter PFS and survival.
  • CONCLUSION: Imatinib mesylate was well tolerated but had minimal single-agent activity in patients with recurrent ovarian or primary peritoneal carcinoma.
  • No marker was identified that would predict activity of imatinib; however, tumor p-AKT and plasma VEGF levels were associated with poor outcome.
  • [MeSH-major] Neoplasm Recurrence, Local / drug therapy. Neoplasms, Glandular and Epithelial / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy. Piperazines / administration & dosage. Pyrimidines / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Benzamides. Biomarkers, Tumor / analysis. DNA Mutational Analysis. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Enzyme-Linked Immunosorbent Assay. Female. Follow-Up Studies. Humans. Imatinib Mesylate. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Neoplasm Staging. Probability. Risk Assessment. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18612157.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA27469; United States / NCI NIH HHS / CA / CA37517; United States / NCI NIH HHS / CA / CA83638
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Biomarkers, Tumor; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


27. Horton TM, Thompson PA, Berg SL, Adamson PC, Ingle AM, Dolan ME, Delaney SM, Hedge M, Weiss HL, Wu MF, Blaney SM, Children's Oncology Group Study: Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. J Clin Oncol; 2007 Nov 1;25(31):4922-8
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study.
  • Pretreatment leukemia cell O6-methylguanine-DNA methyltransferase (MGMT) activity, tumor and plasma MGMT promoter methylation, and microsatellite instability (MSI) were examined in 14 of 16 study patients and in tissue bank samples from children with acute leukemia not treated with temozolomide (MGMT, n = 67; MSI, n = 65).
  • Leukemia cell MGMT activity was higher in pediatric ALL than AML (P < .0001).
  • [MeSH-major] Antineoplastic Agents, Alkylating / pharmacokinetics. Dacarbazine / analogs & derivatives. Drug Resistance, Neoplasm / genetics. Leukemia / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17971589.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K12CA90433; United States / NCI NIH HHS / CA / P30 CA14599; United States / NCI NIH HHS / CA / U01CA63187; United States / NCI NIH HHS / CA / UO1-CA97452
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


28. Kalyani A, Rohaizak M, Cheong SK, Nor Aini U, Balasundaram V, Norlia A: Recurrent multiple myeloma presenting as a breast plasmacytoma. Med J Malaysia; 2010 Sep;65(3):227-8
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent multiple myeloma presenting as a breast plasmacytoma.
  • We describe a patient with multiple myeloma, who initially responded to chemotherapy and went into remission.
  • Further treatment with radiotherapy, thalidomide and later second line chemotherapy appeared unsuccessful and she showed rapid disease progression with rising paraproteins and new extramedullary plasmacytoma lesions in the forehead, supraclavicular region, nasopharynx, liver, spleen, pancreas and paraaortic lymph nodes.
  • [MeSH-major] Breast Neoplasms / pathology. Multiple Myeloma / pathology. Neoplasm Recurrence, Local / pathology. Plasmacytoma / pathology
  • [MeSH-minor] Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21939175.001).
  • [ISSN] 0300-5283
  • [Journal-full-title] The Medical journal of Malaysia
  • [ISO-abbreviation] Med. J. Malaysia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Malaysia
  •  go-up   go-down


29. Kiura K, Nakagawa K, Shinkai T, Eguchi K, Ohe Y, Yamamoto N, Tsuboi M, Yokota S, Seto T, Jiang H, Nishio K, Saijo N, Fukuoka M: A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol; 2008 Apr;3(4):386-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer.
  • INTRODUCTION: Vandetanib (ZACTIMA) is a once-daily, oral anticancer drug that selectively inhibits vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) signaling.
  • PATIENTS AND METHODS: Eligible patients with locally advanced or metastatic (stage IIIB/IV) or recurrent non-small cell lung cancer, previously treated with chemotherapy, were randomized to receive once-daily oral vandetanib 100, 200, or 300 mg (1:1:1).
  • Baseline plasma VEGF levels appeared to be lower in patients who experienced clinical benefit after vandetanib treatment.
  • CONCLUSION: In Japanese patients with advanced non-small cell lung cancer, vandetanib monotherapy (100-300 mg/d) demonstrated antitumor activity with an acceptable safety and tolerability profile.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Piperidines / administration & dosage. Quinazolines / administration & dosage
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / epidemiology. Adenocarcinoma / secondary. Administration, Oral. Adult. Aged. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / secondary. Double-Blind Method. Female. Humans. Japan / epidemiology. Male. Maximum Tolerated Dose. Middle Aged. Mutation / genetics. Prognosis. Receptor, Epidermal Growth Factor / genetics

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379357.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 0 / Piperidines; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


30. Hatakeyama H, Cheng H, Wirth P, Counsell A, Marcrom SR, Wood CB, Pohlmann PR, Gilbert J, Murphy B, Yarbrough WG, Wheeler DL, Harari PM, Guo Y, Shyr Y, Slebos RJ, Chung CH: Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. PLoS One; 2010 Sep 13;5(9):e12702
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma.
  • BACKGROUND: We hypothesized that chronic inhibition of epidermal growth factor receptor (EGFR) by cetuximab, a monoclonal anti-EGFR antibody, induces up-regulation of its ligands resulting in resistance and that microRNAs (miRs) play an important role in the ligand regulation in head and neck squamous cell carcinoma (HNSCC).
  • METHODOLOGY/PRINCIPAL FINDINGS: Genome-wide changes in gene and miR expression were determined in cetuximab-sensitive cell line, SCC1, and its resistant derivative 1Cc8 using DNA microarrays and RT-PCR.
  • Stimulation with HB-EGF induced cetuximab resistance in sensitive cell lines.
  • Inhibition of HB-EGF and the addition of miR-212 mimic induced cetuximab sensitivity in resistant cell lines.
  • MicroRNA-212 and HB-EGF expression were inversely correlated in an additional 33 HNSCC and keratinocyte cell lines.
  • Six tumors and 46 plasma samples from HNSCC patients were examined for HB-EGF levels.
  • HB-EGF plasma levels were lower in newly diagnosed HNSCC patients when compared to patients with recurrent disease.
  • The combination of EGFR ligand inhibitors or miR modulators with cetuximab may improve the clinical outcome of cetuximab therapy in HNSCC.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2006 Aug 15;66(16):8210-8 [16912200.001]
  • [Cites] Mol Cell. 2004 Dec 22;16(6):861-5 [15610730.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jun 22;358(1):12-7 [17475218.001]
  • [Cites] Science. 2007 May 18;316(5827):1039-43 [17463250.001]
  • [Cites] Mol Cancer Ther. 2007 Jun;6(6):1683-91 [17541031.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3230-7 [17664471.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8486-93 [17875687.001]
  • [Cites] Nat Rev Genet. 2008 Feb;9(2):102-14 [18197166.001]
  • [Cites] Oncogene. 2008 Jun 26;27(28):3944-56 [18297114.001]
  • [Cites] N Engl J Med. 2008 Sep 11;359(11):1116-27 [18784101.001]
  • [Cites] Mol Cancer Ther. 2008 Oct;7(10):3441-51 [18852147.001]
  • [Cites] Cell. 2009 Jan 23;136(2):215-33 [19167326.001]
  • [Cites] Clin Cancer Res. 2009 Apr 1;15(7):2397-405 [19276250.001]
  • [Cites] Am J Physiol Renal Physiol. 2009 May;296(5):F957-65 [19244405.001]
  • [Cites] Am J Clin Oncol. 2011 Dec;34(6):581-6 [21217396.001]
  • [Cites] Cell Struct Funct. 2006;31(1):1-14 [16508205.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] J Cell Sci. 2005 Jun 1;118(Pt 11):2363-70 [15923649.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9455-62 [16230409.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):8105-8 [16299242.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8686-98 [16361555.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] Nature. 2000 Mar 16;404(6775):293-6 [10749213.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]
  • [Cites] Gastroenterology. 2001 Jul;121(1):68-78 [11438495.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3221-6 [12621152.001]
  • [Cites] Exp Cell Res. 2003 Mar 10;284(1):2-13 [12648462.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):1980-7 [12743152.001]
  • [Cites] Semin Oncol. 2003 Jun;30(3 Suppl 7):3-14 [12840796.001]
  • [Cites] J Cell Biol. 2003 Nov 10;163(3):489-502 [14597771.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):77-85 [14701768.001]
  • [Cites] Science. 2004 Jan 2;303(5654):95-8 [14631048.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] Cytokine Growth Factor Rev. 2004 Feb;15(1):13-9 [14746810.001]
  • [Cites] J Cell Biol. 2004 Mar 1;164(5):769-79 [14993236.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] J Biol Chem. 1984 Jun 25;259(12):7755-60 [6330079.001]
  • [Cites] Mol Biol Cell. 1995 Aug;6(8):967-80 [7579712.001]
  • [Cites] Nature. 1997 Feb 20;385(6618):729-33 [9034190.001]
  • [Cites] Biochim Biophys Acta. 1997 Dec 9;1333(3):F179-99 [9426203.001]
  • [Cites] J Natl Cancer Inst. 1998 Jun 3;90(11):824-32 [9625170.001]
  • [Cites] Development. 1999 Jun;126(12):2739-50 [10331984.001]
  • [Cites] J Biol Chem. 1999 Sep 3;274(36):25906-12 [10464334.001]
  • [Cites] Oncogene. 2007 Mar 29;26(14):2006-16 [17001310.001]
  • (PMID = 20856931.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA113448; United States / NIDCR NIH HHS / DE / R01 DE017982; United States / NCI NIH HHS / CA / R01-CA-113448; United States / NIDCR NIH HHS / DE / R01-DE-017982
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / HBEGF protein, human; 0 / Heparin-binding EGF-like Growth Factor; 0 / Intercellular Signaling Peptides and Proteins; 0 / MIRN212 microRNA, human; 0 / MicroRNAs; PQX0D8J21J / Cetuximab
  • [Other-IDs] NLM/ PMC2938338
  •  go-up   go-down


31. Dietzfelbinger H: [Monoclonal gammopathy--multiple myeloma]. MMW Fortschr Med; 2005 Jun 16;147(24):32-3, 35-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Monoclonal gammopathy--multiple myeloma].
  • The diagnosis of monoclonal gammopathy of undetermined significance (MGUS), requires both the detection of monoclonal gammopathy by immunofixation on the one hand, and the exclusion of signs of multiple myeloma (MM) on the other.
  • The possibility of an MM should be considered in particular in elderly patients with an elevated ESR, anemia, recurrent infections and hypercalcemia.
  • The diagnosis of MM is established on the basis of a constellation of major and minor criteria that includes characteristic results of serum and urine electrophoresis and immunofixation, routine lab and bone marrow (plasma cell infiltration) studies as well as complications (anemia, renal failure, hypercalcemia, osteolysis).
  • Standard chemotherapy comprises melphalan-prednisone or chemotherapy VAD.
  • Improved results have been achieved with high-dose chemotherapy plus various forms of stem cell transplantation.
  • [MeSH-major] Multiple Myeloma / diagnosis. Paraproteinemias / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromosome Deletion. Chromosomes, Human, Pair 13. Early Diagnosis. Humans. Neoplasm Staging. Palliative Care. Prognosis. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16001531.001).
  • [ISSN] 1438-3276
  • [Journal-full-title] MMW Fortschritte der Medizin
  • [ISO-abbreviation] MMW Fortschr Med
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


32. Torre V, Cavallari V, Bucolo S, Abbate G, Romano G, Fera G, Galletti B: [Description of a particular case of the so-called Schmincke lymphoepithelioma and study of the correlation with Epstein-Barr virus]. Acta Otorhinolaryngol Ital; 2000 Oct;20(5):347-53

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For poorly differentiated rhinopharyngeal carcinomas, the clinical presentation (association with the Epstein-Barr virus, paraneoplastic syndromes, onset of lymphoma) and the histopathological features can be polymorphous and they can confound or delay diagnosis and preparation of an adequate treatment plan (radio-chemotherapy).
  • Here an observation of this type is presented in a young patient (19 years old) who came under observation for a laterocervical tumefaction recurrent from a previous exeresis performed at another hospital and symptoms of serotine febricula, dysphagia and serology positive for the Epstein-Barr virus (EBV).
  • The particular histology of the neoformation lies in the abundant infiltration of plasma cell and lymphocyte eosinophils, at times in blastic form.
  • Moreover, elements with a large clear nucleus and evident nucleolus (Hodgkin-like) and scattered multinucleate Langhans-type giant cells can be seen.
  • In the former case we find an attempt to limit the carcinomatous process; in the latter it is a response caused by the EBV and is not, apparently, aimed at protecting against the neoplasm rather it facilitates the neoplastic process.
  • [MeSH-major] Carcinoma, Squamous Cell / virology. Epstein-Barr Virus Infections / complications. Nasopharyngeal Neoplasms / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11284263.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


33. Karnak I, Senocak ME, Ciftci AO, Cağlar M, Bingöl-Koloğlu M, Tanyel FC, Büyükpamukçu N: Inflammatory myofibroblastic tumor in children: diagnosis and treatment. J Pediatr Surg; 2001 Jun;36(6):908-12
Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory myofibroblastic tumor in children: diagnosis and treatment.
  • BACKGROUND/PURPOSE: Inflammatory myofibroblastic tumor (IMT) is a rare benign neoplasm.
  • Although it is commonly seen in children, the number of childhood cases in the current literature is limited.
  • Furthermore, malignant degeneration or transformation to lymphoma in the recurrent or residual IMT have directed attention to this interesting entity.
  • Herein, the authors present their experience with IMT with special emphasis on diagnosis and treatment.
  • Total surgical excision of IMT was considered adequate for treatment in 6 cases.
  • One patient with aggressive IMT required further treatments such as immunomodulation and chemotherapy and died of neutropenic sepsis.
  • CONCLUSIONS: IMT is a benign neoplasm rarely presented with malignant features such as local invasiveness, recurrence, distant metastasis, or malignant transformation.
  • Complete surgical resection and close follow-up are all necessary for appropriate treatment to avoid recurrences as well as unnecessary and potentially harmful therapy.
  • The optimal management of locally aggressive and recurrent forms should be decided individually for each patient.
  • [MeSH-major] Abdominal Neoplasms / pathology. Abdominal Neoplasms / surgery. Granuloma, Plasma Cell / pathology. Granuloma, Plasma Cell / surgery
  • [MeSH-minor] Child. Female. Humans. Male. Recurrence. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 by W.B. Saunders Company.
  • (PMID = 11381424.001).
  • [ISSN] 0022-3468
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 21
  •  go-up   go-down


34. Megat Shiraz MA, Jong YH, Primuharsa Putra SH: Extramedullary plasmacytoma in the maxillary sinus. Singapore Med J; 2008 Nov;49(11):e310-1
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extramedullary plasmacytoma is a rare malignant plasma cell tumour.
  • A 56-year-old man presented with recurrent epistaxis and acute anaemia.
  • Histopathology examination of the maxillary mass revealed abundant plasma cells with kappa-chain restriction.
  • He was planned for four cycles of chemotherapy.
  • Unfortunately, in view of the advanced stage of disease, he succumbed to his disease during the first cycle of chemotherapy.
  • [MeSH-minor] Anemia / complications. Antineoplastic Agents / therapeutic use. Fatal Outcome. Humans. Magnetic Resonance Imaging / methods. Male. Maxillary Sinus / pathology. Maxillary Sinus / radiography. Middle Aged. Nasopharynx / pathology. Neoplasm Metastasis. Plasmacytoma / diagnosis. Plasmacytoma / pathology. Plasmacytoma / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19037537.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


35. Pivot X, Chamorey E, Guardiola E, Magné N, Thyss A, Otto J, Giroux B, Mouri Z, Schneider M, Milano G: Phase I and pharmacokinetic study of the association of capecitabine-cisplatin in head and neck cancer patients. Ann Oncol; 2003 Oct;14(10):1578-86
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The combination of cisplatin and 5-fluorouracil (5-FU) is considered to be the standard treatment in induction chemotherapy for patients with squamous cell carcinoma of the head and neck.
  • Capecitabine (Xeloda) is an oral fluoropyrimidine that is preferentially activated at the tumoral level, exploiting the higher thymidine phosphorylase activity in tumoral tissue.
  • This phase I trial was conducted in patients with locally recurrent or metastatic head and neck carcinoma.
  • The treatment plan included cisplatin on day 1 every 21 days, followed by capecitabine twice daily from day 2 to day 15, with a 1-week rest period.
  • Pharmacokinetic investigations concerned plasma measurement of unchanged capecitabine, 5'-deoxy-5-fluorocytidine, 5'-doxifluridine and 5-FU using an optimized high performance liquid chromatography method, and cisplatin measurement in plasma using a limited sampling procedure.
  • There was no evidence of pharmacokinetic-pharmacodynamic relationships with the drugs and metabolites investigated.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14504061.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


36. Goldstein MJ, Mitchell EP: Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest; 2005;23(4):338-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It can be measured in serum quantitatively, and its level in plasma can be useful as a marker of disease.
  • Frequent monitoring of CEA postoperatively may allow identification of patients with metastatic disease for whom surgical resection or other localized therapy might be potentially beneficial.
  • To identify this group, serial CEA measurement appears to be more effective than clinical evaluation or any other diagnostic modality, although its sensitivity for detecting recurrent disease is not as high for locoregional or pulmonary metastases as it is for liver metastases.
  • In the follow-up of patients undergoing palliative therapy, the CEA level correlates well with response, and CEA is indicative of not only response but may also identify patients with stable disease for whom there is also a demonstrated benefit in survival and symptom relief with combination chemotherapy.
  • Immunotherapy based on CEA is a rapidly advancing area of clinical research demonstrating antibody and T-cell responses.
  • [MeSH-minor] Follow-Up Studies. Humans. Immunohistochemistry. Neoplasm Staging. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16100946.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen
  • [Number-of-references] 181
  •  go-up   go-down


37. Tejada-Berges T, Granai CO, Gordinier M, Gajewski W: Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer. Expert Rev Anticancer Ther; 2002 Apr;2(2):143-50
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer.
  • The pharmacokinetics of this polyethylene-glycol-coated liposome are characterized by a reduced volume of distribution, a long intravascular circulating half-life and slow plasma clearance compared with free doxorubicin.
  • The FDA and EMEA have approved its use for the treatment of AIDS-related Kaposi's sarcoma and, more recently, for recurrent epithelial ovarian cancer (EOC).
  • Numerous investigations have focused on its use in the treatment of metastatic breast cancer, as well as recurrent squamous cell cervical carcinoma, soft tissue sarcoma, squamous head and neck cancers, prostate cancers and malignant gliomas.
  • Ongoing clinical studies of combination regimens incorporating Caelyx/Doxil will further clarify its role in the treatment of advanced solid tumors.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Breast Neoplasms / drug therapy. Doxorubicin / administration & dosage. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Animals. Clinical Trials as Topic / methods. Clinical Trials as Topic / statistics & numerical data. Female. Humans. Neoplasm Recurrence, Local / drug therapy


38. El-Sahwi K, Bellone S, Cocco E, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli FA, Hui P, Rüttinger D, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD: Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201). Mol Cancer Ther; 2010 Jan;9(1):57-66
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated the expression of epithelial cell adhesion molecule (EpCAM) and the potential of MT201 (adecatumumab), a human monoclonal antibody against EpCAM, in uterine serous papillary carcinoma (USPC).
  • EpCAM expression was evaluated by real-time PCR and immunohistochemistry in a total of 56 USPC fresh-frozen biopsies and paraffin-embedded tissues.
  • EpCAM surface expression was also evaluated by flow cytometry and immunohistochemistry in six USPC cell lines.
  • Sensitivity to MT201 antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity was tested against a panel of primary USPC cell lines expressing different levels of EpCAM in standard 5-h (51)Cr release assays.
  • High surface expression of EpCAM was found in 83% (five out of six) of the USPC cell lines tested by flow cytometry.
  • EpCAM-positive cell lines were found highly sensitive to MT201-mediated antibody-dependent cellular cytotoxicity in vitro, whereas primary USPC cell lines were resistant to natural killer cell-dependent cytotoxicity.
  • Human plasma IgG did not significantly inhibit MT201-mediated cytotoxicity against USPC.
  • MT201 might represent a novel therapeutic strategy in patients harboring advanced/recurrent or metastatic USPC refractory to standard treatment modalities.

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2002 Jul 1;100(1):101-10 [12115595.001]
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2001 Jun;15(3):433-46 [11476564.001]
  • [Cites] Gynecol Oncol. 2003 Jul;90(1):181-5 [12821361.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4782-91 [14581349.001]
  • [Cites] Br J Cancer. 2004 May 4;90(9):1814-24 [15208622.001]
  • [Cites] Am J Surg Pathol. 1982 Mar;6(2):93-108 [7102898.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] Cancer Metastasis Rev. 1983;2(4):337-50 [6203638.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Oct;83(20):7893-7 [3094017.001]
  • [Cites] Int J Cancer. 1986 Nov 15;38(5):631-6 [3770992.001]
  • [Cites] J Immunol. 1987 May 15;138(10):3566-72 [2437198.001]
  • [Cites] Cancer Invest. 1987;5(4):285-91 [2444316.001]
  • [Cites] Br J Cancer. 1991 Feb;63(2):275-8 [1997106.001]
  • [Cites] Am J Surg Pathol. 1992 Jun;16(6):600-10 [1599038.001]
  • [Cites] Transfus Med Rev. 1991 Apr;5(2):123-31 [1726550.001]
  • [Cites] Gynecol Oncol. 1992 Sep;46(3):317-21 [1526508.001]
  • [Cites] Gynecol Oncol. 1992 Dec;47(3):298-305 [1473741.001]
  • [Cites] J Clin Invest. 1993 Jan;91(1):123-32 [7678599.001]
  • [Cites] Gynecol Oncol. 1994 Sep;54(3):264-8 [8088602.001]
  • [Cites] Int J Gynecol Pathol. 1995 Jan;14(1):30-8 [7883423.001]
  • [Cites] Cancer Res. 1995 Jun 15;55(12):2627-34 [7540106.001]
  • [Cites] Clin Obstet Gynecol. 1996 Sep;39(3):686-95 [8862892.001]
  • [Cites] Clin Cancer Res. 1995 Jan;1(1):63-70 [9815888.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1561-73 [15785748.001]
  • [Cites] Br J Cancer. 2006 Mar 13;94(5):642-6 [16495918.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):483-8 [16678891.001]
  • [Cites] Curr Opin Mol Ther. 2007 Apr;9(2):190-6 [17458174.001]
  • [Cites] Clin Cancer Res. 2007 Jul 1;13(13):3899-905 [17606723.001]
  • [Cites] Am J Pathol. 2007 Aug;171(2):386-95 [17600130.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Nat Cell Biol. 2009 Feb;11(2):162-71 [19136966.001]
  • [Cites] J Mol Med (Berl). 1999 Oct;77(10):699-712 [10606205.001]
  • [Cites] Lancet. 2000 Dec 9;356(9246):1981-2 [11130529.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):4105-11 [11358833.001]
  • [Cites] Gynecol Oncol. 2002 Oct;87(1):8-16 [12468336.001]
  • (PMID = 20053761.001).
  • [ISSN] 1538-8514
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA122728-01A2; United States / NCI NIH HHS / CA / R01 CA122728-01A2; United States / NCI NIH HHS / CA / R01 CA122728; United States / NCI NIH HHS / CA / CA-16359; United States / NCI NIH HHS / CA / P30 CA016359
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Cell Adhesion Molecules; 0 / Immunoglobulin G; 0 / Interleukin-2; 0 / MT201 antibody, human; 0 / RNA, Messenger; 0 / tumor-associated antigen GA733
  • [Other-IDs] NLM/ NIHMS159166; NLM/ PMC2806489
  •  go-up   go-down


39. Pieras-Ayala E, Palou-Redorta J, Tomero-Ruiz JI, Montlleó-González M, Salvador-Bayarri J, Vicente-Rodríguez J: Prognostic value of cystocopically pseudotumoral lesions (inflammation/granuloma) in primary stage T1 grade 3 bladder tumors treated with BCG. Int Urol Nephrol; 2001;33(3):469-72
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The aim of this study is to find out whether the pseudotumoral lesions (inflammation/granuloma) seen at the follow-up cystoscopy performed three to six months after transurethral resection of primary stage T1 grade 3 bladder tumor and instillations of BCG therapy might have some prognostic value as far as recurrence and/or long term progression are concerned.
  • MATERIAL AND METHODS: From the first group of one hundred and thirteen patients with primary stage of T1 grade 3 bladder tumor treated with 81 mg of BCG Connaught (weekly/during six weeks), those with recurrent tumor at the 3rd and 6th month were excluded, so we evaluated 99 patients.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. BCG Vaccine / therapeutic use. Cystoscopy. Granuloma, Plasma Cell / pathology. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Disease Progression. Humans. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Urol. 1987 Dec;60(6):543-8 [3501324.001]
  • [Cites] J Urol. 1990 Mar;143(3):502-6 [2106041.001]
  • [Cites] J Urol. 2000 Jan;163(1):73-8 [10604317.001]
  • [Cites] J Urol. 1996 Feb;155(2):477-82 [8558640.001]
  • [Cites] J Urol. 1986 Feb;135(2):261-4 [3511283.001]
  • [Cites] Arch Esp Urol. 2001 Apr;54(3):211-7 [11432035.001]
  • [Cites] Eur Urol. 2000;37 Suppl 1:9-15 [10575266.001]
  • [Cites] J Urol. 1996 Nov;156(5):1602-5 [8863547.001]
  • [Cites] J Urol. 1986 Feb;135(2):268-71 [3511285.001]
  • [Cites] Urol Res. 1992;20(3):219-28 [1615584.001]
  • [Cites] Urology. 1999 Aug;54(2):258-63 [10443721.001]
  • [Cites] J Urol. 1987 Jan;137(1):39-43 [3795364.001]
  • [Cites] Eur Urol. 1998;34(1):67-72 [9676417.001]
  • [Cites] J Urol. 2000 Dec;164(6):2129-33 [11061941.001]
  • [Cites] Br J Urol. 1995 Feb;75(2):188-92 [7850324.001]
  • [Cites] Urology. 1985 Feb;25(2):119-23 [3881870.001]
  • [Cites] J Urol. 1990 Dec;144(6):1399-400 [2231934.001]
  • [Cites] Urology. 1992 Aug;40(2):175-9 [1502759.001]
  • [Cites] J Urol. 1976 Aug;116(2):180-3 [820877.001]
  • [Cites] J Urol. 1989 Jan;141(1):22-9 [2908949.001]
  • [Cites] J Urol. 1988 May;139(5):941-4 [3361668.001]
  • [Cites] J Urol. 1988 Oct;140(4):751-4 [3418796.001]
  • [Cites] Eur Urol. 2000;37 Suppl 1:1-8 [10575265.001]
  • (PMID = 12230274.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / BCG Vaccine
  •  go-up   go-down


40. McMeekin DS, Sill MW, Darcy KM, Stearns-Kurosawa DJ, Webster K, Waggoner S, Benbrook D: A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study. Gynecol Oncol; 2007 Sep;106(3):596-603
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To evaluate the efficacy and adverse events (AEs) of thalidomide in previously treated, measurable, persistent or recurrent leiomyosarcoma (LMS) of the uterus, and to explore associations between angiogenic markers and treatment or clinical outcome.
  • Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and soluble endothelial protein C receptor (sEPCR) were evaluated in pre- and post-treatment serum and plasma.
  • Treatment with thalidomide was associated with a significant decrease in plasma bFGF (p=0.008) and serum sEPCR (p=0.006), but not in plasma VEGF.
  • Plasma VEGF was associated with increased risk of progression (hazard ratio [HR]=3.5; 95% confidence interval (CI)=1.5-7.8; p=0.003) and death (HR=4.7; 95% CI=1.6-13.8; p=0.005) after adjusting for GOG performance status.
  • The association between pretreatment VEGF and prognosis in this population supports further evaluation of anti-angiogenic therapies in uterine LMS.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Leiomyosarcoma / blood supply. Leiomyosarcoma / drug therapy. Thalidomide / therapeutic use. Uterine Neoplasms / blood supply. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antigens, CD / blood. Biomarkers, Tumor / blood. Dose-Response Relationship, Drug. Female. Fibroblast Growth Factor 2 / blood. Humans. Middle Aged. Neoplasm Recurrence, Local / blood supply. Neoplasm Recurrence, Local / drug therapy. Neovascularization, Pathologic / blood. Neovascularization, Pathologic / drug therapy. Proportional Hazards Models. Receptors, Cell Surface / blood. Vascular Endothelial Growth Factor A / blood

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17597196.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / PROCR protein, human; 0 / Receptors, Cell Surface; 0 / Vascular Endothelial Growth Factor A; 103107-01-3 / Fibroblast Growth Factor 2; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


41. Kaufmann SH, Karp JE, Letendre L, Kottke TJ, Safgren S, Greer J, Gojo I, Atherton P, Svingen PA, Loegering DA, Litzow MR, Sloan JA, Reid JM, Ames MM, Adjei AA, Erlichman C: Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia. Clin Cancer Res; 2005 Sep 15;11(18):6641-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia.
  • PURPOSE: To assess the maximum tolerated dose, toxicities, pharmacokinetics, and antileukemic activity of topotecan and carboplatin in adults with recurrent or refractory acute leukemias.
  • Plasma topotecan and ultrafilterable platinum were assayed on days 1 to 5.
  • RESULTS: Fifty-one patients received a total of 69 courses of therapy.
  • Dose-limiting toxicity consisted of grade 4/5 typhlitis and grade 3/4 mucositis after one course of therapy or grade 4 neutropenia and thrombocytopenia lasting >50 days when a second course was administered on day 21.
  • Topotecan steady-state plasma concentrations increased with dose.
  • No accumulation of topotecan or ultrafilterable platinum occurred between days 1 and 5 of therapy.
  • Leukemic cell levels of topoisomerase I, checkpoint kinase 1, checkpoint kinase 2, and Mcl-1 correlated with proliferating cell nuclear antigen but not with response.
  • Responses seem to correlate with low pretreatment blast cell Bcl-2 expression.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia / drug therapy
  • [MeSH-minor] Acute Disease. Adult. Aged. Bone Marrow Cells / drug effects. Bone Marrow Cells / metabolism. Carboplatin / administration & dosage. Carboplatin / adverse effects. Carboplatin / pharmacokinetics. Cell Cycle Proteins / metabolism. Combined Modality Therapy. DNA Topoisomerases, Type I / metabolism. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Female. HL-60 Cells. Hematopoietic Stem Cell Transplantation. Humans. Immunoblotting. Infusions, Intravenous. Male. Middle Aged. Neoplasm Recurrence, Local. Proliferating Cell Nuclear Antigen / metabolism. Topotecan / administration & dosage. Topotecan / adverse effects. Topotecan / pharmacokinetics. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16166443.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA73709; United States / NCI NIH HHS / CA / U01 CA69854; United States / NCI NIH HHS / CA / U01 CA69912
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Proliferating Cell Nuclear Antigen; 7M7YKX2N15 / Topotecan; BG3F62OND5 / Carboplatin; EC 5.99.1.2 / DNA Topoisomerases, Type I
  •  go-up   go-down






Advertisement